Compare GALT & PNTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GALT | PNTG |
|---|---|---|
| Founded | 2000 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 261.1M | 1.0B |
| IPO Year | N/A | N/A |
| Metric | GALT | PNTG |
|---|---|---|
| Price | $4.08 | $28.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $8.50 | ★ $35.33 |
| AVG Volume (30 Days) | ★ 803.2K | 247.6K |
| Earning Date | 11-14-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.47 |
| EPS | N/A | ★ 0.75 |
| Revenue | N/A | ★ $847,274,000.00 |
| Revenue This Year | N/A | $36.42 |
| Revenue Next Year | N/A | $23.99 |
| P/E Ratio | ★ N/A | $38.88 |
| Revenue Growth | N/A | ★ 29.89 |
| 52 Week Low | $0.94 | $21.18 |
| 52 Week High | $7.13 | $30.46 |
| Indicator | GALT | PNTG |
|---|---|---|
| Relative Strength Index (RSI) | 35.60 | 55.04 |
| Support Level | $3.90 | $28.99 |
| Resistance Level | $4.19 | $29.91 |
| Average True Range (ATR) | 0.60 | 0.66 |
| MACD | -0.22 | -0.20 |
| Stochastic Oscillator | 16.25 | 17.28 |
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Pennant Group Inc is engaged in providing healthcare services to patients of all ages, including the growing senior population, in the United States. It operates in multiple lines of business including home health, hospice, and senior living which includes the company's assisted living, independent living, and memory care communities across Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. The company generates majority of its revenue from home health and hospice services segment, which includes its home health, hospice and home care businesses.